Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The ongoing evolution of proteomics in malignancy.

Amit S Dhamoon1, Elise C Kohn, Nilofer S Azad

  • 1Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Dr. MSC 1500, Bethesda, MD 20892, United States.

Drug Discovery Today
|September 11, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial.

Nature communications·2026
Same author

Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer.

The New England journal of medicine·2026
Same author

A case report of acute carcinoid heart failure during lutetium-177 dotatate-triapine treatment for well-differentiated neuroendocrine tumors.

Frontiers in oncology·2026
Same author

Daraxonrasib in Previously Treated Advanced <i>RAS</i>-Mutated Pancreatic Cancer.

The New England journal of medicine·2026
Same author

Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial.

Nature communications·2026
Same author

Ovarian cancer.

Nature reviews. Disease primers·2026
Same journal

From biologics to small-molecule modulators: The evolving landscape of interleukin-targeted therapeutics.

Drug discovery today·2026
Same journal

Targeting the GLP-1 receptor pathways for dual management of obesity and depression.

Drug discovery today·2026
Same journal

Chemical intervention strategies targeting MYC for cancer therapy.

Drug discovery today·2026
Same journal

How many protein pairs can we chemically target?

Drug discovery today·2026
Same journal

From trial-and-error to inverse design: how AI is redefining drug delivery systems.

Drug discovery today·2026
Same journal

Critical evaluation of the key mediators causing life-threatening symptoms during human anaphylaxis.

Drug discovery today·2026
See all related articles

Genomics and proteomics reveal disease mechanisms. Proteomics innovations offer new tools for cancer diagnosis, treatment, and biomarker discovery in patient care.

Area of Science:

  • Genomics and proteomics in molecular medicine.

Background:

  • Genomics defines genetic makeup, while proteomics studies protein function as gene effectors.
  • Proteomics has advanced significantly due to new technologies like mass spectrometry.

Purpose of the Study:

  • To discuss innovations in proteomic technologies.
  • To highlight prospective applications of proteomics in patient care, particularly in clinical oncology.

Main Methods:

  • Protein arrays.
  • Two-dimensional gel electrophoresis.
  • Mass spectrometry.

Main Results:

  • Proteomic techniques show potential for biomarker development.
  • Applications include target validation, diagnosis, and prognosis.

Related Experiment Videos

  • Optimization of treatment strategies in oncology.

    • Conclusions:

    • Proteomic innovations are crucial for advancing medical care.
    • These technologies hold promise for personalized medicine and improved patient outcomes.